Neoadjuvant Therapy

"Neoadjuvant Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.

Descriptor ID	D020360
MeSH Number(s)	E02.186.450
Concept/Terms	Neoadjuvant Therapy Neoadjuvant Therapy Neoadjuvant Therapies Therapies, Neoadjuvant Therapy, Neoadjuvant Neoadjuvant Treatment Neoadjuvant Treatments Treatment, Neoadjuvant Treatments, Neoadjuvant

Below are MeSH descriptors whose meaning is more general than "Neoadjuvant Therapy".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Combined Modality Therapy [E02.186]
Neoadjuvant Therapy [E02.186.450]

Below are MeSH descriptors whose meaning is related to "Neoadjuvant Therapy".

Below are MeSH descriptors whose meaning is more specific than "Neoadjuvant Therapy".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neoadjuvant Therapy" by people in this website by year, and whether "Neoadjuvant Therapy" was a major or minor topic of these publications.

Bar chart showing 12 publications over 9 distinct years, with a maximum of 3 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	0	1	1
2009	0	1	1
2013	0	1	1
2017	0	1	1
2018	1	0	1
2019	1	1	2
2020	1	2	3
2021	0	1	1
2023	0	1	1

Below are the most recent publications written about "Neoadjuvant Therapy" by people in Profiles.

Bansil S, Silva A, Taniguchi A, Wiedmer C, Fernandez M, Pagano I, Vierkoetter K, Killeen J, Fukui J. Racial/Ethnic Differences Among Tumor-Infiltrating Lymphocytes in Breast Cancer Tumors. Oncologist. 2023 02 08; 28(2):116-122.

View in: PubMed
Gu S, Lheureux S, Sayad A, Cybulska P, Hogen L, Vyarvelska I, Tu D, Parulekar WR, Nankivell M, Kehoe S, Chi DS, Levine DA, Bernardini MQ, Rosen B, Oza A, Brown M, Neel BG. Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening. Proc Natl Acad Sci U S A. 2021 06 22; 118(25).

View in: PubMed
Chambers LM, Kuznicki M, Yao M, Chichura A, Gruner M, Reizes O, Debernardo R, Rose PG, Michener C, Vargas R. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer. Gynecol Oncol. 2020 12; 159(3):699-705.

View in: PubMed
Chambers LM, Costales AB, Crean-Tate K, Kuznicki M, Morton M, Horowitz M, Jagielo T, Rose PG, Michener C, Vargas R, Debernardo R. A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology. Gynecol Oncol. 2020 09; 158(3):794-802.

View in: PubMed
Udagawa M, Ohnishi I, Nara A, Sueyoshi K, Arai S, Murase Y, Sugishita T, Gokita K, Watanabe Y, Adikrisna R. [A Case Report of Gastric Cancer Excised after Neoadjuvant Chemotherapy and Long-Term Survival Achieved after NivolumabAdministration for Peritoneal Dissemination]. Gan To Kagaku Ryoho. 2020 Feb; 47(2):325-327.

View in: PubMed
Katyan A, Mittal MK, Mani C, Mandal AK. Strain wave elastography in response assessment to neo-adjuvant chemotherapy in patients with locally advanced breast cancer. Br J Radiol. 2019 Jul; 92(1099):20180515.

View in: PubMed
Fisusi FA, Akala EO. Drug Combinations in Breast Cancer Therapy. Pharm Nanotechnol. 2019; 7(1):3-23.

View in: PubMed
Lammers PE, Dank M, Masetti R, Abbas R, Hilton F, Coppola J, Jacobs I. Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. Br J Cancer. 2018 08; 119(3):266-273.

View in: PubMed
Ma S, Yan T, Liu D, Wang K, Wang J, Song J, Wang T, He W, Bai J, Jin L, Chen X. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma. Thorac Cancer. 2018 02; 9(2):310-315.

View in: PubMed
Ricciardelli C, Lokman NA, Pyragius CE, Ween MP, Macpherson AM, Ruszkiewicz A, Hoffmann P, Oehler MK. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance. Oncotarget. 2017 Mar 14; 8(11):17819-17832.

View in: PubMed

People

Explore

Similar Concepts

Top Journals